Multiple sclerosis (MS)
253 results
1 - 100
Multiple sclerosis (MS) 
Amantadine for fatigue in multiple sclerosis- Intravenous immunoglobulins for multiple sclerosis
- Occupational therapy for multiple sclerosis
- Anticholinergics for urinary symptoms in multiple sclerosis: Cochrane systematic review
- Treatment of seizures in multiple sclerosis
- Hyperbaric oxygen therapy for multiple sclerosis
- Mycophenolate mofetil for relapsing-remitting multiple sclerosis: Cochrane systematic review
- Non pharmacological interventions for spasticity in multiple sclerosis: Cochrane systematic review
- Natalizumab for multiple sclerosis
Alemtuzumab more effective than interferon for multiple sclerosis- Pharmacologic treatment of depression in multiple sclerosis
- Interferon in relapsing‐remitting multiple sclerosis
- Anti‐spasticity agents for multiple sclerosis
- Carnitine for fatigue in multiple sclerosis
- Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis: Cochrane systematic review
- Exercise therapy for multiple sclerosis: Cochrane systematic review
- Cyclophosphamide for multiple sclerosis
- Laquinimod for multiple sclerosis: Cochrane systematic review
- Methotrexate for multiple sclerosis
- Palliative care interventions for people with multiple sclerosis
- Statins for multiple sclerosis: Cochrane systematic review
- Interventions for preventing falls in people with multiple sclerosis
- Neuropsychological rehabilitation for multiple sclerosis: Cochrane systematic review
- Pharmacological treatment for memory disorder in multiple sclerosis: Cochrane systematic review
- Telerehabilitation for persons with multiple sclerosis
- Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews
- Glatiramer acetate for multiple sclerosis
- Exercise therapy for fatigue in multiple sclerosis
- Mitoxantrone for multiple sclerosis: Cochrane systematic review
- Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis
- Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis
- Sodium channel blockers for neuroprotection in multiple sclerosis
- Vitamin D for the management of multiple sclerosis
- Information provision for people with multiple sclerosis
- Azathioprine for people with multiple sclerosis
- Treatment for ataxia in multiple sclerosis
- Dietary interventions for multiple sclerosis‐related outcomes
- Alemtuzumab for multiple sclerosis
- After 15 years, 50% of patients with optic neuritis developed MS (ONTT)
- Psychological interventions for multiple sclerosis
- Oral fingolimod reduces MS recurrence, appears to increase cancer risk
- Cyclophosphamide for multiple sclerosis
- Spasticity
- Psychological interventions for multiple sclerosis
- Polyunsaturated fatty acids for multiple sclerosis
- Aminopyridines for symptomatic treatment in multiple sclerosis
- Corticosteroids or ACTH for acute exacerbations in multiple sclerosis: Cochrane systematic review
- Memory rehabilitation for people with multiple sclerosis
- Pharmacological treatment for chronic central neuropathic pain in people with multiple sclerosis
- Oral versus intravenous steroids for treatment of relapses in multiple sclerosis
- Ocrelizumab for multiple sclerosis
- OB outcomes for those with MS and epilepsy similar to general population; diabetics worse
- Interferon Beta for Primary Progressive Multiple Sclerosis
- Effectiveness of vocational rehabilitation intervention on the return to work and employment of persons with multiple sclerosis
- Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in people with multiple sclerosis
- Siponimod for multiple sclerosis
- Respiratory muscle training for multiple sclerosis
- Rituximab for people with multiple sclerosis